Options therapeutiques chez un patient diabetique de type 2 mal controle par une insuline basale.

[en] In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin. The choice should be made according the individual profile and preference of the patient, in a personalized approach, taking into account the advantages and disadvantages of each therapeutic solution.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Paquot, Nicolas ; Université de Liège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Language :

French

Title :

Options therapeutiques chez un patient diabetique de type 2 mal controle par une insuline basale.

Alternative titles :

[en] Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin

Publication date :

2017

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Special issue title :

Thérapeutique

Volume :

Issue :

571

Pages :

1416-1420

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 September 2017

Statistics

Number of views

235 (4 by ULiège)

Number of downloads

404 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95.
Scheen AJ, Paquot N. Actualisation 2015 du traitement de lhyperglycémie dans le diabète de type 2. Rev Med Suisse 2015;11:1518-25.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
H emmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: Systematic review of randomised clinical trials with meta-Analyses and trial sequential analyses. BMJ 2012; 344:e1771.
Dalal MR, Grabner M, Bonine N, et al. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract 2016;121:17-26.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary. Endocr Pract 2017;23:207-238.
A merican Diabetes Association. Standards of medical care in diabetes 2017. Diabetes Care 2017;40:S1-S135.
M eneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? Am J Med 2013;126:S28-37.
Raccah D. Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. Diabetes Metab 2017;43:110-24.
Scheen AJ, Paquot N. Optimisation dun traitement par insuline basale chez le patient diabétique de type 2. Rev Med Liege 2017;72:156-61.
Vos RC, van Avendonk MJ, Jansen H, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev 2016; 9:CD006992.
S trange P. Treat-To-Target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1:540-8.
S cheen AJ, Schmitt H, Jiang HH, et al. Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes. Diabetes Metab 2017;43:69-78.
P ettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev 2016;32:478-96.
Goldman J, Kapitza C, Pettus J, et al. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin 2017;1-26.
Woo VC. A review of the clinical efficacy and safety of insulin degludec and glargine 300 U /mL in the treatment of diabetes mellitus. Clin Ther 2017; epub ahead of print.
Raccah D, Chou E, Colagiuri S, et al. A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. Diabetes Metab Res Rev 2017;33.
Owens DR. Stepwise intensification of insulin therapy in type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. Diabet Med 2013;30:276-88.
S cheen AJ, Schmitt H, Jiang HH, et al. Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab 2015;41:216-22.
Downie M, Kilov G, Wong J. Initiation and intensification strategies in type 2 diabetes management: A comparison of basal plus and premix regimens. Diabetes Ther 2016;7:641-57.
S cheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43-62.
Kim YG, Min SH, Hahn S, et al. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-Analysis. Diabetes Res Clin Pract 2016;116:86-95.
S cheen AJ. Gliptines, sécurité cardio-vasculaire et insuffisance cardiaque: le point après létude TECOS. Rev Med Suisse 2015;11:1526-31.
S cheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 2015;14:505-24.
S cheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-Transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
S cheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2 : dEMPA-REG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
P onikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA ) of the ESC. Eur Heart J 2016;37:2129-200.
Tang H, Cui W, Li D, et al. Sodium-glucose co-Transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-Analysis of randomized controlled trials. Diabetes Obes Metab 2017;19:142-7.
S cheen AJ. SGLT2 inhibitors: Benefit/risk balance. Curr Diabetes Rep 2016;16:92.
B alena R, Hensley IE, Miller S, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: A systematic review of the literature. Diabetes Obes Metab 2013;15:485-502.
Owens DR, Monnier L, Barnett AH. Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes Obes Metab 2017;epub ahead of print.
Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-Acting insulin in patients with type 2 diabetes: Results of a meta-Analysis. Postgrad Med 2017;129:436-45.
Charbonnel B, Bertolini M, Tinahones FJ , et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: A meta-Analysis. J Diabetes Complications 2014;28:880-6.
Scheen AJ, Paquot N. Intérêt dune combinaison agoniste des récepteurs du GLP-1 et insuline basale dans le traitement du diabète de type 2. Rev Med Suisse 2014;10:1549-54.
Giorgino F, Bonadonna RC, Gentile S, et al. Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-Acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev 2016;32:497-511.
Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 trial. Diabetes Care 2016;39:1318-28.
M arso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.
S cheen AJ. Historique des études cardiovasculaires: de lUGDP aux dernières études. Médecine des maladies métaboliques 2017;11:2S15-2S26.
L iakopoulou P, Liakos A, Vasilakou D, et al. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: A systematic review and meta-Analysis. Endocrine 2017;56:485-94.